TARSUS PHARMACEUTICALS, INC. Interest Income, Other
TARSUS PHARMACEUTICALS, INC. (TARS) reported Interest Income, Other of $3.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2026-06-30 was $3.70M, a 12.56% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2026-03-31 was $3.72M, a 7.76% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2025-12-31 was $3.95M, a 8.31% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income, other for the quarter ending 2025-09-30 was $4.11M, a 0.15% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income, other for fiscal 2025 was $15.75M, a 4.88% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. interest income, other for fiscal 2024 was $15.01M, a 45.25% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. interest income, other for fiscal 2023 was $10.34M, a 195.43% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. interest income, other for fiscal 2022 was $3.50M.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.70M 10-Q · filed 2026-08-06 | $7.42M 10-Q · filed 2026-08-06 | $11.37M derived: sum of 3 quarters · filed 2026-08-06 | $15.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.72M 10-Q · filed 2026-05-06 | $7.67M derived: sum of 2 quarters · filed 2026-05-06 | $11.79M derived: sum of 3 quarters · filed 2026-05-06 | $16.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.06M derived: sum of 2 quarters · filed 2026-02-23 | $12.29M derived: sum of 3 quarters · filed 2026-08-06 | $15.75M 10-K · filed 2026-02-23 |
| 2025-09-30 | $4.11M 10-Q · filed 2025-11-04 | $8.34M derived: sum of 2 quarters · filed 2026-08-06 | $11.80M 10-Q · filed 2025-11-04 | $15.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.23M 10-Q · filed 2026-08-06 | $7.68M 10-Q · filed 2026-08-06 | $11.33M derived: sum of 3 quarters · filed 2026-08-06 | $15.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.45M 10-Q · filed 2026-05-06 | $7.10M derived: sum of 2 quarters · filed 2026-05-06 | $11.22M derived: sum of 3 quarters · filed 2026-05-06 | $15.35M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $7.77M derived: sum of 2 quarters · filed 2026-02-23 | $11.90M derived: sum of 3 quarters · filed 2026-02-23 | $15.01M 10-K · filed 2026-02-23 |
| 2024-09-30 | $4.12M 10-Q · filed 2025-11-04 | $8.25M derived: sum of 2 quarters · filed 2025-11-04 | $11.37M 10-Q · filed 2025-11-04 | $14.35M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $4.13M 10-Q · filed 2025-08-06 | $7.25M 10-Q · filed 2025-08-06 | $10.22M derived: sum of 3 quarters · filed 2026-02-23 | $13.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $3.12M 10-Q · filed 2025-05-01 | $6.09M derived: sum of 2 quarters · filed 2026-02-23 | $8.94M derived: sum of 3 quarters · filed 2026-02-23 | $11.16M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $5.82M derived: sum of 2 quarters · filed 2026-02-23 | $8.04M derived: sum of 3 quarters · filed 2026-02-23 | $10.34M 10-K · filed 2026-02-23 |
| 2023-09-30 | $2.84M 10-Q · filed 2024-11-13 | $5.07M derived: sum of 2 quarters · filed 2024-11-13 | $7.36M 10-Q · filed 2024-11-13 | $9.49M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $2.23M 10-Q · filed 2024-08-08 | $4.52M 10-Q · filed 2024-08-08 | $6.65M derived: sum of 3 quarters · filed 2025-02-25 | $7.71M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $2.29M 10-Q · filed 2024-05-08 | $4.42M derived: sum of 2 quarters · filed 2025-02-25 | $5.48M derived: sum of 3 quarters · filed 2025-02-25 | $5.78M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.19M derived: sum of 2 quarters · filed 2025-02-25 | $3.48M derived: sum of 3 quarters · filed 2025-02-25 | $3.50M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.06M 10-Q · filed 2023-11-09 | $1.36M derived: sum of 2 quarters · filed 2023-11-09 | $1.37M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $297.00K 10-Q · filed 2023-08-10 | $311.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $8.00K 10-Q · filed 2022-11-09 | $24.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |